MedPath

Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension.

Not Applicable
Conditions
Subclinical Cushing&#39
s syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension.
Registration Number
JPRN-UMIN000002925
Lead Sponsor
Hiroshima University Hospital Department of Endocrinology and Diabetes mellitus
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

(a) Patients with a history of severe cardiovascular or cerebrovascular disease or renal failure. (b) Patients with aldosterone producing adenoma, Cushing's syndrome and malignant tumor. (c) Patients who have taken ARB, ACEI, aldosterone antagonist or diuretics therapy. (d) Patients have contraindication of Eplerenone and Valsartan. (e) Patients with severe liver damage. (f) Patients are pregnant or patients breast-feeding, potentially pregnant. (g) Patients who are diagnosed to be ineligible by the investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath